Formulation Design of Dry Powders for Inhalation
Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer...
Gespeichert in:
Veröffentlicht in: | Journal of pharmaceutical sciences 2015-10, Vol.104 (10), p.3259-3288 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3288 |
---|---|
container_issue | 10 |
container_start_page | 3259 |
container_title | Journal of pharmaceutical sciences |
container_volume | 104 |
creator | Weers, Jeffry G. Miller, Danforth P. |
description | Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer respirable particles. These technologies have enabled medicinal chemists to focus on molecular design without concern regarding compatibility of physicochemical properties with traditional, blend-based technologies. Therapeutics with diverse physicochemical properties can now be formulated as stable and respirable dry powders. Particle engineering technologies have also driven the deployment of new excipients, giving formulators greater control over particle and powder properties. This plays a key role in enabling efficient delivery of drugs to the lungs. Engineered powder and device combinations enable aerosols that largely bypass the mouth and throat, minimizing the inherent variability among patients that arises from differences in oropharyngeal and airway anatomies and in breathing profiles. This review explores how advances among molecules, particles, and powders have transformed inhaled drug product development. Ultimately, this scientific progress will benefit patients, enabling new classes of therapeutics to be formulated as dry powder aerosols with improved efficacy, reduced variability and side effects, and improved patient adherence. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3259–3288, 2015 |
doi_str_mv | 10.1002/jps.24574 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1710985272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354916301137</els_id><sourcerecordid>1710985272</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4674-497dfa3060eec326f97f31980e2caa1bedd22b52ff35c23614e4a31f9a84c5983</originalsourceid><addsrcrecordid>eNp10MtKAzEUBuAgitbLwheQATe6GJvrXJZSrRcEC-o6pJkTTZmZ1KSj9O1NndaF6CqBfPnP4UfomOALgjEdzubhgnKR8y00IILiNMMk30aD-EZTJni5h_ZDmGGMMyzELtqjGS1X1wHCY-ebrlYL69rkCoJ9bRNnkiu_TCbuswIfEuN8cte-qR4doh2j6gBH6_MAvYyvn0e36cPjzd3o8iHVPMt5ysu8MorFgQCa0cyUuWGkLDBQrRSZQlVROhXUGCY0ZRnhwBUjplQF16Is2AE663Pn3r13EBaysUFDXasWXBckyQkuC0FzGunpLzpznW_jdt8K8ziWRHXeK-1dCB6MnHvbKL-UBMtVjTLWKL9rjPZkndhNG6h-5Ka3CIY9-LQ1LP9PkveTp00k639ALO3DgpdBW2g1VNaDXsjK2T8W-QLEaotX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1710049801</pqid></control><display><type>article</type><title>Formulation Design of Dry Powders for Inhalation</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Weers, Jeffry G. ; Miller, Danforth P.</creator><creatorcontrib>Weers, Jeffry G. ; Miller, Danforth P.</creatorcontrib><description>Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer respirable particles. These technologies have enabled medicinal chemists to focus on molecular design without concern regarding compatibility of physicochemical properties with traditional, blend-based technologies. Therapeutics with diverse physicochemical properties can now be formulated as stable and respirable dry powders. Particle engineering technologies have also driven the deployment of new excipients, giving formulators greater control over particle and powder properties. This plays a key role in enabling efficient delivery of drugs to the lungs. Engineered powder and device combinations enable aerosols that largely bypass the mouth and throat, minimizing the inherent variability among patients that arises from differences in oropharyngeal and airway anatomies and in breathing profiles. This review explores how advances among molecules, particles, and powders have transformed inhaled drug product development. Ultimately, this scientific progress will benefit patients, enabling new classes of therapeutics to be formulated as dry powder aerosols with improved efficacy, reduced variability and side effects, and improved patient adherence. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3259–3288, 2015</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.24574</identifier><identifier>PMID: 26296055</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Inhalation ; aerosols ; Algorithms ; amorphous ; Chemistry, Pharmaceutical - standards ; dry powder inhaler ; Dry Powder Inhalers - standards ; engineered particles ; excipients ; Humans ; inhalation ; Inhaled by design ; Particle Size ; powder technology ; Powders - standards ; protein delivery ; pulmonary delivery/adsorption</subject><ispartof>Journal of pharmaceutical sciences, 2015-10, Vol.104 (10), p.3259-3288</ispartof><rights>2015 Wiley Periodicals, Inc. and the American Pharmacists Association</rights><rights>2015 Wiley Periodicals, Inc. and the American Pharmacists Association.</rights><rights>Copyright © 2015 Wiley Periodicals, Inc., A Wiley Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4674-497dfa3060eec326f97f31980e2caa1bedd22b52ff35c23614e4a31f9a84c5983</citedby><cites>FETCH-LOGICAL-c4674-497dfa3060eec326f97f31980e2caa1bedd22b52ff35c23614e4a31f9a84c5983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.24574$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.24574$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26296055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weers, Jeffry G.</creatorcontrib><creatorcontrib>Miller, Danforth P.</creatorcontrib><title>Formulation Design of Dry Powders for Inhalation</title><title>Journal of pharmaceutical sciences</title><addtitle>J Pharm Sci</addtitle><description>Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer respirable particles. These technologies have enabled medicinal chemists to focus on molecular design without concern regarding compatibility of physicochemical properties with traditional, blend-based technologies. Therapeutics with diverse physicochemical properties can now be formulated as stable and respirable dry powders. Particle engineering technologies have also driven the deployment of new excipients, giving formulators greater control over particle and powder properties. This plays a key role in enabling efficient delivery of drugs to the lungs. Engineered powder and device combinations enable aerosols that largely bypass the mouth and throat, minimizing the inherent variability among patients that arises from differences in oropharyngeal and airway anatomies and in breathing profiles. This review explores how advances among molecules, particles, and powders have transformed inhaled drug product development. Ultimately, this scientific progress will benefit patients, enabling new classes of therapeutics to be formulated as dry powder aerosols with improved efficacy, reduced variability and side effects, and improved patient adherence. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3259–3288, 2015</description><subject>Administration, Inhalation</subject><subject>aerosols</subject><subject>Algorithms</subject><subject>amorphous</subject><subject>Chemistry, Pharmaceutical - standards</subject><subject>dry powder inhaler</subject><subject>Dry Powder Inhalers - standards</subject><subject>engineered particles</subject><subject>excipients</subject><subject>Humans</subject><subject>inhalation</subject><subject>Inhaled by design</subject><subject>Particle Size</subject><subject>powder technology</subject><subject>Powders - standards</subject><subject>protein delivery</subject><subject>pulmonary delivery/adsorption</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MtKAzEUBuAgitbLwheQATe6GJvrXJZSrRcEC-o6pJkTTZmZ1KSj9O1NndaF6CqBfPnP4UfomOALgjEdzubhgnKR8y00IILiNMMk30aD-EZTJni5h_ZDmGGMMyzELtqjGS1X1wHCY-ebrlYL69rkCoJ9bRNnkiu_TCbuswIfEuN8cte-qR4doh2j6gBH6_MAvYyvn0e36cPjzd3o8iHVPMt5ysu8MorFgQCa0cyUuWGkLDBQrRSZQlVROhXUGCY0ZRnhwBUjplQF16Is2AE663Pn3r13EBaysUFDXasWXBckyQkuC0FzGunpLzpznW_jdt8K8ziWRHXeK-1dCB6MnHvbKL-UBMtVjTLWKL9rjPZkndhNG6h-5Ka3CIY9-LQ1LP9PkveTp00k639ALO3DgpdBW2g1VNaDXsjK2T8W-QLEaotX</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Weers, Jeffry G.</creator><creator>Miller, Danforth P.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Formulation Design of Dry Powders for Inhalation</title><author>Weers, Jeffry G. ; Miller, Danforth P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4674-497dfa3060eec326f97f31980e2caa1bedd22b52ff35c23614e4a31f9a84c5983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Administration, Inhalation</topic><topic>aerosols</topic><topic>Algorithms</topic><topic>amorphous</topic><topic>Chemistry, Pharmaceutical - standards</topic><topic>dry powder inhaler</topic><topic>Dry Powder Inhalers - standards</topic><topic>engineered particles</topic><topic>excipients</topic><topic>Humans</topic><topic>inhalation</topic><topic>Inhaled by design</topic><topic>Particle Size</topic><topic>powder technology</topic><topic>Powders - standards</topic><topic>protein delivery</topic><topic>pulmonary delivery/adsorption</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weers, Jeffry G.</creatorcontrib><creatorcontrib>Miller, Danforth P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weers, Jeffry G.</au><au>Miller, Danforth P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Formulation Design of Dry Powders for Inhalation</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J Pharm Sci</addtitle><date>2015-10</date><risdate>2015</risdate><volume>104</volume><issue>10</issue><spage>3259</spage><epage>3288</epage><pages>3259-3288</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer respirable particles. These technologies have enabled medicinal chemists to focus on molecular design without concern regarding compatibility of physicochemical properties with traditional, blend-based technologies. Therapeutics with diverse physicochemical properties can now be formulated as stable and respirable dry powders. Particle engineering technologies have also driven the deployment of new excipients, giving formulators greater control over particle and powder properties. This plays a key role in enabling efficient delivery of drugs to the lungs. Engineered powder and device combinations enable aerosols that largely bypass the mouth and throat, minimizing the inherent variability among patients that arises from differences in oropharyngeal and airway anatomies and in breathing profiles. This review explores how advances among molecules, particles, and powders have transformed inhaled drug product development. Ultimately, this scientific progress will benefit patients, enabling new classes of therapeutics to be formulated as dry powder aerosols with improved efficacy, reduced variability and side effects, and improved patient adherence. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3259–3288, 2015</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26296055</pmid><doi>10.1002/jps.24574</doi><tpages>30</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3549 |
ispartof | Journal of pharmaceutical sciences, 2015-10, Vol.104 (10), p.3259-3288 |
issn | 0022-3549 1520-6017 |
language | eng |
recordid | cdi_proquest_miscellaneous_1710985272 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
subjects | Administration, Inhalation aerosols Algorithms amorphous Chemistry, Pharmaceutical - standards dry powder inhaler Dry Powder Inhalers - standards engineered particles excipients Humans inhalation Inhaled by design Particle Size powder technology Powders - standards protein delivery pulmonary delivery/adsorption |
title | Formulation Design of Dry Powders for Inhalation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T04%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Formulation%20Design%20of%20Dry%20Powders%20for%20Inhalation&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Weers,%20Jeffry%20G.&rft.date=2015-10&rft.volume=104&rft.issue=10&rft.spage=3259&rft.epage=3288&rft.pages=3259-3288&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.24574&rft_dat=%3Cproquest_cross%3E1710985272%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1710049801&rft_id=info:pmid/26296055&rft_els_id=S0022354916301137&rfr_iscdi=true |